World Health Organization
WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator
Abstract
WHO has developed Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products in order to establish globally applicable standards for the conduct of biomedical research on human subjects. A number of countries have no regulations for clinical trials or the regulations require supplementation. In those countries, the relevant health authority may designate, in part or in whole, the WHO GCP Guidelines as the basis on which clinical trials will be conducted. This article discusses the functions, obligations and responsibilities of the investigator as defined in the WHO GCP.
Source and rights
Published by Annals of medicine, 1994. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- World Health Organization
- Published
- 1994
- Applies to
- 🌐 International
- Scope
- International
- Journal
- Annals of medicine
- PubMed
- 8024733
- Added to Prognia
- 24 July 2026
More in other
- The Canine Cognitive Dysfunction Syndrome Working Group guidelines for diagnosis and monitoring of canine cognitive dysfunction syndromeEuropean Respiratory Society · 2026
- Chinese guidelines for the clinical application of antibacterial drugs for febrile neutropenia (2026)Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
